NUCC-390 dihydrochloride |
| Catalog No.GC39573 |
NUCC-390 dihydrochloride is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 dihydrochloride induces internalization of CXCR4 receptor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2749281-71-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NUCC-390 dihydrochloride is a novel and selective small-molecule CXCR4 receptor agonist[1]. NUCC-390 dihydrochloride induces internalization of CXCR4 receptor[2].
NUCC-390 dihydrochloride (0.625μM-1.25μM; 24h) induces axonal growth in primary cultured neurons via CXCR4 in a dose-dependent manner[1].Treatment of HEK293 cells with NUCC-390 dihydrochloride (10μM; 2h) resulted in a marked internalization of CXCR4-YFP, producing distinct receptor aggregates in the cytoplasm, but excluded from the nucleus. The effects of NUCC-390 dihydrochloride were completely inhibited by AMD-3100 (GC14745)[2].
NUCC-390 dihydrochloride (26mg/kg; ip; 14 days) treatment increased the density of actively regenerating axons in the proximal part of the sciatic nerve in mice with sciatic nerve injury, as well as the number of axons entering the bridging zone[3]. The CXCR4 receptor agonist NUCC-390 dihydrochloride (3.2mg/kg; im; 72h) stimulates the recovery of function of the neuromuscular junction after degeneration of motor axon terminals induced by Taipoxin and promotes nerve regeneration after O. scutellatus scutellatus venom muscle injection in mice[4]. NUCC-390 dihydrochloride (3.2mg/kg; 96h) promotes the recovery of evoked junction potentials (EJPs) of neuromuscular junctions of single muscle fibres of the mouse soleus muscles injected with the venoms of Bungarus caeruleus or β‐bungarotoxin[5].
References:
[1]. Negro S, Zanetti G, Mattarei A, et al. An agonist of the CXCR4 receptor strongly promotes regeneration of degenerated motor axon terminals[J]. Cells, 2019, 8(10): 1183.
[2]. Mishra R K, Shum A K, Platanias L C, et al. Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists[J]. Scientific reports, 2016, 6(1): 30155.
[3]. Zanetti G, Negro S, Megighian A, et al. A CXCR4 receptor agonist strongly stimulates axonal regeneration after damage[J]. Annals of Clinical and Translational Neurology, 2019, 6(12): 2395-2402.
[4]. Stazi M, D’Este G, Mattarei A, et al. An agonist of the CXCR4 receptor accelerates the recovery from the peripheral neuroparalysis induced by Taipan snake envenomation[J]. Plos Neglected Tropical Diseases, 2020, 14(9): e0008547.
[5]. Stazi M, Fabris F, Tan K Y, et al. An agonist of the CXCR4 receptor is therapeutic for the neuroparalysis induced by Bungarus snakes envenoming[J]. Clinical and Translational Medicine, 2022, 12(1)
| Cell experiment [1]: | |
Cell lines | Cerebellar granule neurons cell (CGN) |
Preparation Method | Rat cerebellar granule neuron cells (CGN) were treated with the indicated concentrations of NUCC-390 dihydrochloride (0.625μM -1.25μM) for 24h. |
Reaction Conditions | 0.625μM -1.25μM; 24h |
Applications | NUCC-390 dihydrochloride induces axonal growth in primary cultured neurons via CXCR4 in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Evoked Junctional Potentials modle |
Preparation Method | Six to eight-week-old CD1 mice were anesthetized with isoflurane, and locally injected in the hind limb with α-LTx (5μg/kg in 15µl of 0.9% NaCl, 0.2% gelatin solution). Four groups of mice were employed: group 1 received daily hind limb injections of NUCC-390 dihydrochloride (3.2mg/kg), group 2 was ip. injected twice daily with AMD3100 (4mg/kg), group 3 received a combination of the 2 treatments, group 4 only vehicle. Seventy-two hours later mice were sacrificed, and subjected to electrophysiological measurement. |
Dosage form | 3.2mg/kg; ip; 72h |
Applications | NUCC-390 dihydrochloride promotes the recovery of the physiological function of the murine neuromuscular junction (NMJ) after complete degeneration of its motor axon terminal. |
References:
[1]. Negro S, Zanetti G, Mattarei A, et al. An agonist of the CXCR4 receptor strongly promotes regeneration of degenerated motor axon terminals[J]. Cells, 2019, 8(10): 1183.
| Cas No. | 2749281-71-6 | SDF | |
| Canonical SMILES | O=C(N1CCCCC1)C2=NN(CCC)C3=C2CC(NCCC4=CC=NC=C4)CC3.Cl.Cl | ||
| Formula | C23H35Cl2N5O | M.Wt | 468.46 |
| Solubility | DMSO: 250 mg/mL (533.66 mM) | Storage | Store at 2-8°C,stored under nitrogen |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1347 mL | 10.6733 mL | 21.3465 mL |
| 5 mM | 0.4269 mL | 2.1347 mL | 4.2693 mL |
| 10 mM | 0.2135 mL | 1.0673 mL | 2.1347 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *